UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Lancet neurology, ISSN 1474-4422, 2008, Volume 7, Issue 10, pp. 903 - 914
Neurology | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Disability Evaluation | Interferon-beta - administration & dosage | Multiple Sclerosis, Relapsing-Remitting - pathology | Confidence Intervals | Drug Administration Schedule | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Immunologic Factors - administration & dosage | Glatiramer Acetate | Magnetic Resonance Imaging - methods | Male | Treatment Outcome | Disease Progression | Peptides - administration & dosage | Injections, Subcutaneous - methods | Interferon beta-1a | Adolescent | Adult | Female | Retrospective Studies | Medical research | Multiple sclerosis | Care and treatment | Interferon beta | Medicine, Experimental | Comparative analysis | Biological response modifiers | Acetates | Index Medicus | Drugs | Subpopulations | Magnetic resonance imaging | Motivation | copolymer 1 | Clinical trials | Interferon
Journal Article
Drugs (New York, N.Y.), ISSN 0012-6667, 2010, Volume 70, Issue 12, pp. 1545 - 1577
Adis-Drug-Evaluations | Glatiramer-acetate, general | Multiple-sclerosis | Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Adjuvants, Immunologic - administration & dosage | Adjuvants, Immunologic - pharmacology | Humans | Glatiramer Acetate | Multiple Sclerosis - immunology | Adjuvants, Immunologic - therapeutic use | Disease Progression | Peptides - administration & dosage | Peptides - therapeutic use | Multiple Sclerosis - drug therapy | Peptides - pharmacology
Journal Article
JAMA neurology, ISSN 2168-6149, 12/2015, Volume 72, Issue 12, pp. 1433 - 1441
Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Disability Evaluation | Double-Blind Method | Follow-Up Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Treatment Outcome | Young Adult | Magnetic Resonance Imaging | Time Factors | Glatiramer Acetate - therapeutic use | Injections, Subcutaneous | Adolescent | Adult | Female | Multiple Sclerosis - drug therapy | Therapeutic Equivalency
Journal Article
Multiple sclerosis, ISSN 1352-4585, 5/2017, Volume 23, Issue 6, pp. 818 - 829
Glatiramer acetate | low-frequency regimen | annualized relapse rate | safety | relapsing-remitting multiple sclerosis | Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Glatiramer Acetate - pharmacology | Recurrence | Double-Blind Method | Follow-Up Studies | Outcome Assessment (Health Care) | Glatiramer Acetate - administration & dosage | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Male | Multiple Sclerosis, Relapsing-Remitting - physiopathology | Disease Progression | Magnetic Resonance Imaging | Glatiramer Acetate - adverse effects | Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging | Adult | Female | Immunosuppressive Agents - adverse effects | Immunosuppressive Agents - pharmacology | Immunosuppressive Agents - administration & dosage | Drugs | Neuroimaging | Multiple sclerosis | Copolymer 1 | Nuclear magnetic resonance--NMR | Magnetic resonance imaging | Gadolinium | Interferon | Substantia grisea | Index Medicus
Journal Article
Journal of the neurological sciences, ISSN 0022-510X, 2015, Volume 359, Issue 1, pp. 24 - 34
Neurology | Glatiramer acetate | Drugs | Multiple sclerosis | Generic equivalency | Generic | Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Glatiramer Acetate - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Glatiramer Acetate - chemistry | Immunosuppressive Agents - chemistry | Multiple Sclerosis - drug therapy | Therapeutic Equivalency | Polymerization | Drug approval | Biopolymers | Index Medicus
Journal Article
Annals of neurology, ISSN 0364-5134, 06/2013, Volume 73, Issue 6, pp. 705 - 713
Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Prospective Studies | Double-Blind Method | Drug Administration Schedule | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Glatiramer Acetate | Male | Treatment Outcome | Peptides - administration & dosage | Multiple Sclerosis, Relapsing-Remitting - epidemiology | Adult | Female | Immunosuppressive Agents - administration & dosage | Index Medicus
Journal Article
Annals of neurology, ISSN 0364-5134, 03/2013, Volume 73, Issue 3, pp. 327 - 340
Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Disability Evaluation | Double-Blind Method | Humans | Middle Aged | Glatiramer Acetate | Male | Treatment Outcome | Secondary Prevention | Case-Control Studies | Interferon-beta - therapeutic use | Young Adult | Magnetic Resonance Imaging | Analysis of Variance | Adolescent | Adult | Female | Retrospective Studies | Drug Therapy, Combination | Longitudinal Studies | Peptides - therapeutic use | Immunologic Factors - therapeutic use | Multiple Sclerosis - drug therapy | Clinical trials | Multiple sclerosis | Index Medicus
Journal Article
CNS drugs, ISSN 1172-7047, 5/2011, Volume 25, Issue 5, pp. 401 - 414
Pharmacotherapy | Neurology | Neurosciences | Medicine & Public Health | Psychiatry | Psychopharmacology | Glatiramer-acetate, pharmacodynamics | Immunomodulators, pharmacodynamics | Multiple-sclerosis | Pharmacology & Pharmacy | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Biological and medical sciences | Multiple sclerosis and variants. Guillain barrƩ syndrome and other inflammatory polyneuropathies. Leukoencephalitis | Medical sciences | Neuropharmacology | Pharmacology. Drug treatments | Multiple Sclerosis, Relapsing-Remitting - immunology | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Encephalomyelitis, Autoimmune, Experimental - drug therapy | Humans | Encephalomyelitis, Autoimmune, Experimental - immunology | Glatiramer Acetate | Male | Peptides - pharmacology | Animals | Neuroprotective Agents - pharmacology | Multiple Sclerosis - immunology | Female | Mice | Immunosuppressive Agents - pharmacology | Disease Models, Animal | Multiple Sclerosis - drug therapy | Glatiramer acetate | Multiple sclerosis | Antigen presenting cells | Physiological aspects | Research | Drug therapy | Health aspects | Index Medicus
Journal Article
Cochrane library, ISSN 1469-493X, 2010, Volume 2010, Issue 5, pp. CD004678 - CD004678
Recurrence | Multiple sclerosis | Immunosuppressive Agents | Multiple Sclerosis, Chronic Progressive | Peptides | Pharmacological interventions for Multiple Sclerosis | Glatiramer Acetate | Treatment Outcome | Disease Progression | Randomized Controlled Trials as Topic | Neurology | Pharmacological treatments by drug type | Multiple Sclerosis, RelapsingāRemitting | Medicine General & Introductory Medical Sciences | Immunomodulators | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Multiple Sclerosis, Chronic Progressive - drug therapy | Peptides - therapeutic use | Index Medicus
Journal Article